title: A combination of vitamin C and losartan for cisplatin-induced nephrotoxicity in rats.
abstract: BACKGROUND
  The nephroprotective effect of co-administration of vitamin C and losartan as prophylaxis against cisplatin-induced nephrotoxicity (CIN) was evaluated.
  
  
  METHODS
  Co-administration of vitamin C and losartan was compared with losartan (10 mg/kg), vitamin C (250 mg/kg), and placebo in 4 groups of rats with CIN. The prophylactic agents were injected daily for a period of 4 days, and on day 3, a single dose (6 mg/kg) of cisplatin was administrated. The animals were sacrificed 7 days later for pathological examination of the kidneys.
  
  
  RESULTS
  Cisplatin prevented the animals' weight gain. The serum levels of creatinine and blood urea nitrogen increased within the groups with CIN, but no significant difference was observed between the groups. The prophylaxis has no effect on serum osmolality, total protein, or nitrite concentrations. The kidney tissue damage was scored, and losartan provided a lower damage score than vitamin C and a combination of vitamin C and losartan.
  
  
  CONCLUSIONS
  We concluded that co-administration of vitamin C and losartan was not more effective than the administration of vitamin C or losartan alone.
authors.affiliation: Water and Electrolytes Research Center, Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Farzaneh
authors.initials: F
authors.lastname: Ashrafi
authors.forename: Mehdi
authors.initials: M
authors.lastname: Nematbakhsh
authors.forename: Tahereh
authors.initials: T
authors.lastname: Safari
authors.forename: Ardeshir
authors.initials: A
authors.lastname: Talebi
authors.forename: Hamid
authors.initials: H
authors.lastname: Nasri
authors.forename: Mehdi
authors.initials: M
authors.lastname: Khazaei
authors.forename: Mohammad-Mehdi
authors.initials: MM
authors.lastname: Baradaran-Mahdavi
authors.forename: Amir
authors.initials: A
authors.lastname: Jafapisheh
authors.forename: Behrooz
authors.initials: B
authors.lastname: Olia
authors.forename: Omid
authors.initials: O
authors.lastname: Pirhaji
authors.forename: Sayyed-Javad
authors.initials: SJ
authors.lastname: Hashemi-Nia
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Eshraghi
authors.forename: Zahra
authors.initials: Z
authors.lastname: Pezeshki
authors.forename: Mojgan
authors.initials: M
authors.lastname: Mortazavi
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001205:Ascorbic Acid / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins / Q000378:metabolism; D001806:Blood Urea Nitrogen; D002945:Cisplatin; D003404:Creatinine / Q000097:blood; D019610:Cytoprotection; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D019808:Losartan / Q000494:pharmacology*; D008297:Male; D009573:Nitrites / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000975:Antioxidants; D015415:Biomarkers; D001798:Blood Proteins; D009573:Nitrites; D003404:Creatinine; D019808:Losartan; D001205:Ascorbic Acid; D002945:Cisplatin